A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive said on Wednesday. The U.S.

HYDERABAD, India (Reuters) - Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company ...

HYDERABAD, India, Feb 26 (Reuters) - Drugmaker Merck (MRK.N), opens new tab, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the ...

MSD’s HIV treatment is now back on track after ... which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds.

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

announces a license and research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify Cryptigen™ tumor-specific antigens (TSAs) in an undisclosed ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasil, a ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...